ProCE Banner Activity

Inclusivity in Studies of LA ART and LA PrEP: Implications From CROI 2024 for Western Europe

Conference Coverage
Clinical Thought

Long-acting injectable ART and PrEP are revolutionizing HIV treatment and prevention, respectively. These studies presented at CROI 2024 demonstrate how healthcare professionals and investigators can work to ensure inclusive access to long-acting therapies for all people at risk for and living with HIV.

Released: March 20, 2024

Expiration: March 19, 2025

Share

Faculty

Cristina Mussini

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: Gilead, Johnson & Johnson, ViiV.